Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2023-07-06 Regulatory Filings
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Pacific Edge Limited (“PEB”) – Trading Halt Lifted
Regulatory Filings Classification · 95% confidence The document is a short memorandum from NZX Limited notifying market participants that the trading halt on Pacific Edge Limited shares has been lifted following an announcement. It contains no financial data, no detailed report, and is essentially a regulatory market notice. The document length is only 662 characters, indicating it is a brief announcement rather than a full report. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-06 English
Pacific Edge Welcomes Stay of Novitas LCD
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Pacific Edge welcomes a stay of a Local Coverage Determination (LCD) by Novitas, which affects Medicare coverage of their Cxbladder product in the US. It discusses regulatory and procedural developments related to Medicare coverage but does not contain financial statements, detailed financial results, or management discussion of financial performance. The document is short (3312 characters) and serves as an update on regulatory and operational matters rather than a formal financial report or filing. It is not an earnings release, annual report, or interim report. It is also not a regulatory filing in the sense of officer certifications or compliance documents, but rather a general regulatory announcement about Medicare coverage status. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-07-06 English
Pacific Edge Limited (“PEB”) – Trading Halt of Securities
Regulatory Filings Classification · 95% confidence The document is a memorandum from NZX Limited announcing a trading halt on Pacific Edge Limited's securities. It mentions the halt was placed at the issuer's request and is expected to be lifted after a material announcement. There is no financial data, report, or detailed analysis present. The document is a regulatory announcement related to trading status, not a financial report or detailed filing. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-07-06 English
Pacific Edge Welcomes Stay of Novitas LCD 2 pages 114.8KB
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a regulatory decision affecting Medicare coverage of a product (Cxbladder) in the US. It discusses a stay of a Local Coverage Determination (LCD) by Novitas and First Coast, which impacts Medicare reimbursement. The text includes statements from company executives and legal counsel, and provides background on the company and product. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (3312 characters) and serves as a news update or regulatory announcement rather than a formal financial report or filing. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is not a voting result, management change, or capital update. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about Medicare coverage and related legal/regulatory developments affecting the company.
2023-07-05 English
Pacific Edge Updates Billing Policies for US Testing
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 3 July 2023 from Pacific Edge regarding updates to its billing policies for US testing of its Cxbladder diagnostic tests. It discusses changes in patient responsibility and insurance coverage following a Medicare Local Coverage Determination (LCD) that may cease Medicare coverage for these tests. The document does not contain financial statements, detailed financial performance data, or comprehensive management discussion. It is a specific operational update related to billing policies and insurance coverage, not a financial report, earnings release, or regulatory filing. The document length is 4392 characters, which is relatively short and focused on a policy update rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update that does not fit other specific categories.
2023-07-02 English
Pacific Edge Updates Billing Policies for US Testing 2 pages 314.4KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 3 July 2023 from Pacific Edge regarding updates to its billing policies for US testing of its Cxbladder diagnostic tests. It discusses changes in patient responsibility and the impact of a Medicare coverage determination. The content is focused on operational and policy updates rather than financial results, regulatory filings, or detailed financial data. The document is relatively short (4392 characters) and does not contain financial statements or detailed financial analysis. It is not a report, transcript, or regulatory filing but rather a corporate announcement about billing policy changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous company announcements that do not fit other specific categories.
2023-07-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.